Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis

Twelve weeks sofosbuvir/velpatasvir (SOF/VEL) is a highly effective pan‐genotypic regimen for hepatitis C. Phase 2 data suggest 8 weeks of treatment may be sufficient for previously untreated noncirrhotic patients with genotype 3 (GT3) infection. To maximize the number of patients potentially cured...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyle, Alison, Marra, Fiona, Peters, Erica, Datta, Shouren, Ritchie, Trina, Priest, Matthew, Heydtmann, Mathis, Barclay, Stephen T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155106/
https://www.ncbi.nlm.nih.gov/pubmed/31756019
http://dx.doi.org/10.1111/jvh.13239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155106/
https://www.ncbi.nlm.nih.gov/pubmed/31756019
http://dx.doi.org/10.1111/jvh.13239

Ejemplares similares